Compare BGT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGT | TNGX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.8M | 5.1B |
| IPO Year | 2004 | 2020 |
| Metric | BGT | TNGX |
|---|---|---|
| Price | $10.64 | $29.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $21.78 |
| AVG Volume (30 Days) | 110.3K | ★ 6.4M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $10.22 | $5.34 |
| 52 Week High | $12.75 | $34.39 |
| Indicator | BGT | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 53.88 |
| Support Level | $10.61 | $27.65 |
| Resistance Level | $10.85 | $34.39 |
| Average True Range (ATR) | 0.08 | 2.05 |
| MACD | 0.01 | -0.25 |
| Stochastic Oscillator | 50.00 | 26.85 |
Blackrock Floating Rate Income Trust is a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The company, as a secondary objective, also focuses on preservation of capital to the extent consistent with its primary objective of high current income. The Trust seeks to achieve its investment objectives by investing in worl-wide portfolio of floating rate securities, including investing a substantial amount in U.S. and non-U.S. senior secured floating rate loans (Senior Loans), made to corporate and other business entities.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.